17.94

15.44% 2.40

After Hours: 17.85 -0.09 -0.50%

Summit Therapeutics Inc (SMMT)

Overview News Price History Option Chain Financials Why SMMT Down? Discussions Forecast

Summit Therapeutics Inc stock is traded at $17.94, with a volume of 5.26M. It is up +15.44% in the last 24 hours and up +14.41% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Previous Close:

$15.54

Open:

$15.93

24h Volume:

5.26M

Relative Volume:

2.05

Market Cap:

$13.91B

Revenue:

$220.00K

Net Income/Loss:

$-1.08B

P/E Ratio:

-12.42

EPS:

-1.4448

Net Cash Flow:

$-326.53M

1W Performance:

+15.00%

1M Performance:

+14.41%

6M Performance:

-11.45%

1Y Performance:

-11.36%

1-Day Range:

$15.84

$17.98

1-Week Range:

$15.25

$17.98

52-Week Range:

$13.83

$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name

Summit Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

305-203-2034

Address

601 BRICKELL KEY DRIVE, MIAMI

Employee

265

Twitter

@summitplc

Next Earnings Date

2026-02-23

Latest SEC Filings

SMMT's Discussions on Twitter

Compare SMMT vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SMMT Summit Therapeutics Inc	17.94	12.05B	220.00K	-1.08B	-326.53M	-1.4448
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Downgrade	Jefferies	Buy → Hold
Dec-17-25	Upgrade	Barclays	Underweight → Equal Weight
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Underweight
Sep-04-25	Initiated	Guggenheim	Buy
Aug-19-25	Initiated	Piper Sandler	Neutral
Jul-01-25	Initiated	UBS	Buy
Jun-11-25	Initiated	Leerink Partners	Underperform
Mar-26-25	Upgrade	Citigroup	Neutral → Buy
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform
Feb-28-25	Initiated	Goldman	Buy
Jan-08-25	Initiated	Truist	Buy
Dec-11-24	Initiated	Wells Fargo	Overweight
Dec-06-24	Initiated	Jefferies	Buy
Nov-04-24	Initiated	JMP Securities	Mkt Outperform
Sep-27-24	Downgrade	Citigroup	Buy → Neutral
Aug-12-24	Initiated	H.C. Wainwright	Buy
May-07-24	Initiated	Citigroup	Buy
Mar-26-24	Initiated	Stifel	Buy
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy
Feb-13-18	Initiated	BTIG Research	Buy
Jan-04-18	Initiated	SunTrust	Buy
Dec-01-17	Resumed	H.C. Wainwright	Buy
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform
Oct-05-16	Reiterated	Needham	Buy
Sep-16-16	Initiated	H.C. Wainwright	Buy
Mar-30-15	Initiated	Needham	Buy
Mar-30-15	Initiated	Oppenheimer	Outperform

View All

Summit Therapeutics Inc Stock (SMMT) Latest News

Mar 25, 2026

Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Yahoo Finance UK

Mar 25, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - Yahoo Finance

Mar 25, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool

Mar 25, 2026

U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's

Mar 25, 2026

Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade

Mar 25, 2026

Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - MarketBeat

Mar 25, 2026